[A21-156] Risankizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Last updated 01.03.2022
Project no.:
A21-156
Commission:
Commission awarded on 01.12.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Adult patients with active psoriatic arthritis who have had an inadequate response or who have been intolerant to a prior therapy with disease-modifying antirheumatic drugs (DMARDs)
- Adults with active psoriatic arthritis who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy: added benefit not proven.
- Adults with active psoriatic arthritis who have had an inadequate response or who have been intolerant to a prior therapy with biologic disease-modifying antirheumatic drugs (bDMARDs): added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-41 | Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-133 | Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V | Commission completed |